CAPR

Rating neutralAI Memo

Capricor Therapeutics

As of 2026-04-18/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-04-18 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

StealthX Phase 1 final data expected in Q2 2026 • 2026-06-30

Expected move: +6%

Biggest risk

The bear case is that CAPR remains effectively a binary regulatory story with zero 2025 revenue, rising operating expense, and a negative deterministic prior; any FDA setback could sharply impair commercialization timing and partner monetization despite the strong cash balance [#8-K-2026-03-12][#10-K-2026-03-17].

Invalidation

Break below $16 or thesis failure.

What would change my mind?

The core bull case is that deramiocel is already in active FDA review with a defined August 22, 2026 decision date, HOPE-3 hit primary and key secondary endpoints, the manufacturing site is operational, and cash of about $318 million gives runway through 2027 [#8-K-2026-03-12].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-04-18

Base target

$31

p=40%

Bull target

$50

p=30%

Bear target

$16

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Commercial launch conversion and partner economics after any approval
The core bull case is that deramiocel is already in active FDA review with a defined August 22, 2026 decision date, HOPE-3 hit primary and key secondary endpoints, the manufacturing site is operational, and cash of about $318 million gives runway through 2027 [#8-K-2026-03-12].
At $34.7, the stock already reflects meaningful approval optionality relative to its roughly $1.13 billion market cap, so upside likely requires clean FDA approval plus credible launch conversion; without that, the cash-rich balance sheet alone is not enough to justify an aggressive bullish multiple.

BearKey bullets

Cash runway is solid through 2027, but further delays could eventually revive dilution risk.
Commercial launch readiness fails to translate into payer, physician, or partner traction even after approval.
FDA issues a complete response letter or extends review beyond August 22, 2026.

WatchKey bullets

StealthX Phase 1 final data expected in Q2 2026

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $31 (p=40%)

Bull/Bear spread: +72% / -45%

Vs latest close: Bull +72% · Base +6% · Bear -45%

Scenario probabilities

Bull Target: $50 (p=30%)Base Target: $31 (p=40%)Bear Target: $16 (p=30%)

Commentary

This remains a cautious monitoring setup rather than a high-conviction bullish thesis. Primary-source evidence is strong around the FDA timeline, manufacturing readiness, and cash runway, but forward value realization is still dominated by one binary regulatory event and post-approval execution. That caution fits the deterministic score, which still leans negative with only middling evidence quality and elevated uncertainty.

As of 2026-04-18 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Commercial launch conversion and partner economics after any approval

Scenarios

Bull Target (Scenario probability)

$50 / p=30% prob

Base Target (Scenario probability)

$31 / p=40% prob

Bear Target (Scenario probability)

$16 / p=30% prob

Price $29 as of 2026-05-28

Nearest Scenario: Base (∆ 6%)

Targets vs latest close: Bull +72% · Base +6% · Bear -45%

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-06-30
StealthX Phase 1 final data expected in Q2 2026
The company said the NIAID-sponsored Phase 1 StealthX exosome vaccine study remains ongoing and that final results are expected in the second quarter of 2026, subject to trial completion; this is secondary to deramiocel but can influence platform optionality [#8-K-2026-03-12].
Prob 70.00% • Move 12.00% • Priced-in 25.00%
EVENT2026-08-22
FDA action on deramiocel BLA
Capricor said deramiocel is under FDA review as a Class 2 resubmission with a PDUFA target action date of August 22, 2026; approval would likely unlock first commercial revenues while a CRL would likely reset the thesis materially [#8-K-2026-03-12].
Prob 50.00% • Move 45.00% • Priced-in 45.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Commercial launch conversion and partner economics after any approval
2026-12-31
Capricor said its San Diego GMP facility completed FDA pre-license inspection remediation and is operational for an initial launch, while the 10-K describes Nippon Shinyaku commercialization economics in Japan and a European term sheet that could add upfront and milestone value if finalized; execution here matters, but visibility is still limited before the FDA decision [#8-K-2026-03-12][#10-K-2026-03-17].
Prob 55% • Move 22% • Priced-in 20%

Risks

Cash runway is solid through 2027, but further delays could eventually revive dilution risk.
Commercial launch readiness fails to translate into payer, physician, or partner traction even after approval.
FDA issues a complete response letter or extends review beyond August 22, 2026.
StealthX data disappoint or remain low-signal, leaving CAPR as an even narrower single-asset story.

Peers

Symbol	Summary
INBX	Small-cap biotech peer with similar financing sensitivity and single-asset execution risk, though not a Duchenne-focused comp.
PHAR	Rare-disease commercial biotech peer useful for small-cap specialty-pharma context, but mechanistically and indication-wise a loose comparison.
EVO	Similar market-cap biotech comparator for balance-sheet and development-stage framing, though not a direct operating peer.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-04-18

AI Stock Memo: CAPR - Capricor Therapeutics - RankAlpha